Thermo Fisher Scientific Daclizumab Chimeric Recombinant Mouse Monoclonal Antibody (Daclizumab)

Thermo Fisher Scientific Daclizumab Chimeric Recombinant Mouse Monoclonal Antibody (Daclizumab)

Applications

• Flow Cytometry (Flow): Assay-dependent
• Inhibition Assays (IA): Assay-dependent

Product Specifications

Product Specific Information

Binds to p55 chain of IL2R on human T cells (Tac antigen), which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.

Target Information

Humanized IgG1 monoclonal antibody that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25).
Daclizumab is composed of human (90%) and murine (10%) antibody sequences.

• Human sequences: derived from constant domains of human IgG1 and variable framework regions of Eu myeloma antibody
• Murine sequences: derived from complementarity-determining regions of a murine anti-Tac antibody

On April 22, 2008, Roche Registration Limited voluntarily withdrew marketing authorization for Zenapax (daclizumab), used for prophylaxis of acute organ rejection in renal transplantation, for commercial reasons not related to safety concerns.
Later, Biogen and Abbvie’s Zinbryta (daclizumab) was approved by the FDA in 2016 for the treatment of adult patients with relapsing forms of multiple sclerosis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.